Cancer gene therapy: hard lessons and new courses
- PMID: 10680008
- DOI: 10.1038/sj.gt.3301084
Cancer gene therapy: hard lessons and new courses
Abstract
Gene therapy for the treatment of cancer was initiated with high levels of optimism and enthusiasm. Recently, this perception has had to be tempered by the realisation that efficiency and accuracy of gene delivery remain the most significant barriers to its success. So far, there has been a disappointing inability to reach target cells with sufficient efficacy to generate high enough levels of direct killing and this has necessitated the invocation of bystander effects in order for any potential strategy to be convincing. At least in the foreseeable future, clinical advance will come from co-operation with other more established disciplines - such as chemotherapy, radiotherapy and immunotherapy. This is inevitable - and necessary - in order to prove that gene therapy can have efficacy as part of a combinatorial therapy, before hoping to move clinical mountains alone. In addition, there will have to be a thorough understanding of the clinical situations in which gene therapy will be used in order both to understand its own limitations, and to exploit its full potential. This will enable it to find the appropriate clinical niche in which its abilities will be optimally useful. Finally, anyone wishing to practise clinical cancer gene therapy will rapidly have to learn the ways of the free market and be able to juggle commercial necessities with ideological purity. Gene Therapy (2000) 7, 2-8.
Similar articles
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Targeted gene-delivery strategies for angiostatic cancer treatment.Trends Mol Med. 2007 May;13(5):200-9. doi: 10.1016/j.molmed.2007.03.001. Epub 2007 Mar 26. Trends Mol Med. 2007. PMID: 17379575 Review.
-
Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.Curr Opin Mol Ther. 1999 Aug;1(4):471-9. Curr Opin Mol Ther. 1999. PMID: 11713762 Review.
-
Adenoviral strategies for the gene therapy of cancer.Semin Oncol. 2005 Dec;32(6):573-82. doi: 10.1053/j.seminoncol.2005.09.001. Semin Oncol. 2005. PMID: 16338423 Review.
-
Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.Gene Ther. 2004 Mar;11(6):497-503. doi: 10.1038/sj.gt.3302238. Gene Ther. 2004. PMID: 14762396 Review.
Cited by
-
Stem cell transplantation.BMJ. 2000 Aug 12;321(7258):433-7. doi: 10.1136/bmj.321.7258.433. BMJ. 2000. PMID: 10938056 Free PMC article. Review. No abstract available.
-
Efficient dose-dependent and time-dependent protein transduction of pancreatic carcinoma cells in vitro and in vivo using purified VP22-EGFP fusion protein.J Mol Med (Berl). 2003 Mar;81(3):205-13. doi: 10.1007/s00109-003-0421-3. Epub 2003 Mar 18. J Mol Med (Berl). 2003. PMID: 12682729
-
Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following "suicide" gene therapy in a murine colon carcinoma model.Cancer Immunol Immunother. 2004 Nov;53(11):946-54. doi: 10.1007/s00262-004-0553-5. Epub 2004 Jun 4. Cancer Immunol Immunother. 2004. PMID: 15185012 Free PMC article.
-
Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.ACS Nano. 2025 Apr 15;19(14):13685-13704. doi: 10.1021/acsnano.4c14625. Epub 2025 Apr 2. ACS Nano. 2025. PMID: 40176316 Free PMC article.
-
Lipofection with estrone-based luminophores featuring aggregation-induced emission properties.RSC Adv. 2020 May 27;10(33):19643-19647. doi: 10.1039/d0ra03608k. eCollection 2020 May 20. RSC Adv. 2020. PMID: 35515436 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical